# US 2025/0144211 A1 · Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144211 A1
- Document ID: US20250144211A1
- Status: Published application
- Kind: A1
- Application number: 18/836,523
- Filed: 2023-02-07
- Published: 2025-05-08
- Earliest claimed: 2022-02-07
- Assignees: Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Applicants: Seattle Children's Hospital D/B/A Seattle Children's Research Institute
- Inventors: Shannon Oda
- Web page: https://patentgrep.com/patent/US20250144211A1

## CPC

- A61K 40/30: characterised by the recombinant expression of specific molecules in the cells of the immune system
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/40: characterised by antigens that are targeted or presented by cells of the immune system
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- A61K 35/00: Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding are described. The recombinant proteins include an extracellular domain of an inhibitory immune cell protein and an intracellular domain of a stimulatory immune cell protein connected via a transmembrane domain. The recombinant proteins can be used to stimulate immune cell activation in the fight against cancers and infectious diseases, among other uses.

## Claims

### Claim 1

A protein comprising
an extracellular domain of Fas, CD200R, or SIRPα;
an intracellular domain of HVEM, CD2, CD226, CRTAM, HAVCR1, SLAMF3, SLAMF5, SLAMF7, DR3, CD30, or LIGHT; and
a transmembrane domain linking the extracellular domain to the intracellular domain.

### Claim 2 (depends on 1)

The protein of claim 1, wherein
the extracellular domain is an extracellular domain of Fas and the intracellular domain is an intracellular domain of HVEM, CD30, DR3, LIGHT, CD2, CD226, CRTAM, HAVCR1, SLAMF3, SLAMF5, or SLAMF7;
the extracellular domain is an extracellular domain of CD200R and the intracellular domain is an intracellular domain of CD2, CD226, CRTAM, HAVCR1, SLAMF3, SLAMF5, SLAMF7, CD30, DR3, HVEM, or LIGHT; or
the extracellular domain is an extracellular domain of SIRPα and the intracellular domain is an intracellular domain of CD2, CD226, CRTAM, HAVCR1, SLAMF3, SLAMF5, SLAMF7, CD30, DR3, HVEM, or LIGHT.

### Claim 3 (depends on 1)

The protein of claim 1, wherein
the extracellular domain comprises an extracellular domain of Fas and the intracellular domain comprises an intracellular domain of HVEM;
the extracellular domain comprises an extracellular domain of Fas and the intracellular domain comprises an intracellular domain of CD2;
the extracellular domain comprises an extracellular domain of Fas and the intracellular domain comprises an intracellular domain of CD226;
the extracellular domain comprises an extracellular domain of Fas and the intracellular domain comprises an intracellular domain of CRTAM;
the extracellular domain comprises an extracellular domain of Fas and the intracellular domain comprises an intracellular domain of HAVCR1;
the extracellular domain comprises an extracellular domain of Fas and the intracellular domain comprises an intracellular domain of SLAMF3;
the extracellular domain comprises an extracellular domain of Fas and the intracellular domain comprises an intracellular domain of SLAMF5;
the extracellular domain comprises an extracellular domain of Fas and the intracellular domain comprises an intracellular domain of SLAMF7;
the extracellular domain comprises an extracellular domain of Fas and the intracellular domain comprises an intracellular domain of CD30;
the extracellular domain comprises an extracellular domain of Fas and the intracellular domain comprises an intracellular domain of DR3;
the extracellular domain comprises an extracellular domain of Fas and the intracellular domain comprises an intracellular domain of LIGHT;
the extracellular domain comprises an extracellular domain of CD200R and the intracellular domain comprises an intracellular domain of CD2;
the extracellular domain comprises an extracellular domain of CD200R and the intracellular domain comprises an intracellular domain of CD226;
the extracellular domain comprises an extracellular domain of CD200R and the intracellular domain comprises an intracellular domain of CRTAM;
the extracellular domain comprises an extracellular domain of CD200R and the intracellular domain comprises an intracellular domain of HAVCR1;
the extracellular domain comprises an extracellular domain of CD200R and the intracellular domain comprises an intracellular domain of SLAMF3;
the extracellular domain comprises an extracellular domain of CD200R and the intracellular domain comprises an intracellular domain of SLAMF5;
the extracellular domain comprises an extracellular domain of CD200R and the intracellular domain comprises an intracellular domain of SLAMF7;
the extracellular domain comprises an extracellular domain of CD200R and the intracellular domain comprises an intracellular domain of CD30;
the extracellular domain comprises an extracellular domain of CD200R and the intracellular domain comprises an intracellular domain of DR3;
the extracellular domain comprises an extracellular domain of CD200R and the intracellular domain comprises an intracellular domain of HVEM;
the extracellular domain comprises an extracellular domain of CD200R and the intracellular domain comprises an intracellular domain of LIGHT;
the extracellular domain comprises an extracellular domain of SIRPα and the intracellular domain comprises an intracellular domain of CD2;
the extracellular domain comprises an extracellular domain of SIRPα and the intracellular domain comprises an intracellular domain of CD226;
the extracellular domain comprises an extracellular domain of SIRPα and the intracellular domain comprises an intracellular domain of CRTAM;
the extracellular domain comprises an extracellular domain of SIRPα and the intracellular domain comprises an intracellular domain of HAVCR1;
the extracellular domain comprises an extracellular domain of SIRPα and the intracellular domain comprises an intracellular domain of SLAMF3;
the extracellular domain comprises an extracellular domain of SIRPα and the intracellular domain comprises an intracellular domain of SLAMF5;
the extracellular domain comprises an extracellular domain of SIRPα and the intracellular domain comprises an intracellular domain of SLAMF7;
the extracellular domain comprises an extracellular domain of SIRPα and the intracellular domain comprises an intracellular domain of CD30;
the extracellular domain comprises an extracellular domain of SIRPα and the intracellular domain comprises an intracellular domain of DR3;
the extracellular domain comprises an extracellular domain of SIRPα and the intracellular domain comprises an intracellular domain of HVEM; or the extracellular domain comprises an extracellular domain of SIRPα and the intracellular domain comprises an intracellular domain of LIGHT.

### Claim 4 (depends on 1)

The protein of claim 1, wherein
the extracellular domain comprises an extracellular domain of Fas, the intracellular domain comprises an intracellular domain of HVEM, and the transmembrane domain comprises a transmembrane domain of Fas;
the extracellular domain comprises an extracellular domain of Fas, the intracellular domain comprises an intracellular domain of HVEM, and the transmembrane domain comprises a transmembrane domain of HVEM;
the extracellular domain comprises an extracellular domain of Fas, the intracellular domain comprises an intracellular domain of CD30, and the transmembrane domain comprises a transmembrane domain of Fas;
the extracellular domain comprises an extracellular domain of Fas, the intracellular domain comprises an intracellular domain of CD30, and the transmembrane domain comprises a transmembrane domain of CD30;
the extracellular domain comprises an extracellular domain of Fas, the intracellular domain comprises an intracellular domain of DR3, and the transmembrane domain comprises a transmembrane domain of DR3;
the extracellular domain comprises an extracellular domain of Fas, the intracellular domain comprises an intracellular domain of LIGHT, and the transmembrane domain comprises a transmembrane domain of Fas;
the extracellular domain comprises an extracellular domain of CD200R, the intracellular domain comprises an intracellular domain of CD2, and the transmembrane domain comprises a transmembrane domain of CD28;
the extracellular domain comprises an extracellular domain of CD200R, the intracellular domain comprises an intracellular domain of CD226, and the transmembrane domain comprises a transmembrane domain of CD28;
the extracellular domain comprises an extracellular domain of CD200R, the intracellular domain comprises an intracellular domain of CRTAM, and the transmembrane domain comprises a transmembrane domain of CD28;
the extracellular domain comprises an extracellular domain of CD200R, the intracellular domain comprises an intracellular domain of HAVCR1, and the transmembrane domain comprises a transmembrane domain of CD28;
the extracellular domain comprises an extracellular domain of CD200R, the intracellular domain comprises an intracellular domain of SLAMF3, and the transmembrane domain comprises a transmembrane domain of CD28;
the extracellular domain comprises an extracellular domain of CD200R, the intracellular domain comprises an intracellular domain of SLAMF5, and the transmembrane domain comprises a transmembrane domain of CD28;
the extracellular domain comprises an extracellular domain of CD200R, the intracellular domain comprises an intracellular domain of SLAMF7, and the transmembrane domain comprises a transmembrane domain of CD28;
the extracellular domain comprises an extracellular domain of SIRPα, the intracellular domain comprises an intracellular domain of CD2, and the transmembrane domain comprises a transmembrane domain of CD28;
the extracellular domain comprises an extracellular domain of SIRPα, the intracellular domain comprises an intracellular domain of CD226, and the transmembrane domain comprises a transmembrane domain of CD28;
the extracellular domain comprises an extracellular domain of SIRPα, the intracellular domain comprises an intracellular domain of CRTAM, and the transmembrane domain comprises a transmembrane domain of CD28;
the extracellular domain comprises an extracellular domain of SIRPα, the intracellular domain comprises an intracellular domain of HAVCR1, and the transmembrane domain comprises a transmembrane domain of CD28;
the extracellular domain comprises an extracellular domain of SIRPα, the intracellular domain comprises an intracellular domain of SLAMF3, and the transmembrane domain comprises a transmembrane domain of CD28;
the extracellular domain comprises an extracellular domain of SIRPα, the intracellular domain comprises an intracellular domain of SLAMF5, and the transmembrane domain comprises a transmembrane domain of CD28; or
the extracellular domain comprises an extracellular domain of SIRPα, the intracellular domain comprises an intracellular domain of SLAMF7, and the transmembrane domain comprises a transmembrane domain of CD28.

### Claim 5 (depends on 1)

The protein of claim 1, wherein the intracellular domain comprises the sequence as set forth in SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 40, or SEQ ID NO: 41
or a sequence having at least 90% or 95% sequence identity to the sequence as set forth in SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 40, or SEQ ID NO: 41.

### Claim 6 (depends on 1)

The protein of claim 1, having the sequence as set forth in SEQ ID NO: 65, SEQ ID NO: 69, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, or SEQ ID NO: 77
or a sequence having at least 90% or 95% sequence identity to the sequence as set forth in SEQ ID NO: 65, SEQ ID NO: 69, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, or SEQ ID NO: 77.

### Claim 7

A protein comprising
an extracellular domain of Fas, CD200R, or SIRPα;
an intracellular domain of CD40, ICOS, SLAMF1, CD27, GITR, or OX40; and
a transmembrane domain linking the extracellular domain to the intracellular domain.

### Claim 8 (depends on 7)

The protein of claim 7, wherein
the extracellular domain comprises an extracellular domain of Fas, the intracellular domain comprises an intracellular domain of CD27, and the transmembrane domain comprises a transmembrane domain of Fas;
the extracellular domain comprises an extracellular domain of Fas, the intracellular domain comprises an intracellular domain of CD27, and the transmembrane domain comprises a transmembrane domain of CD27;
the extracellular domain comprises an extracellular domain of Fas, the intracellular domain comprises an intracellular domain of CD40, and the transmembrane domain comprises a transmembrane domain of Fas;
the extracellular domain comprises an extracellular domain of Fas, the intracellular domain comprises an intracellular domain of CD40, and the transmembrane domain comprises a transmembrane domain of CD40;
the extracellular domain comprises an extracellular domain of Fas, the intracellular domain comprises an intracellular domain of GITR, and the transmembrane domain comprises a transmembrane domain of Fas;
the extracellular domain comprises an extracellular domain of Fas, the intracellular domain comprises an intracellular domain of GITR, and the transmembrane domain comprises a transmembrane domain of GITR;
the extracellular domain comprises an extracellular domain of Fas, the intracellular domain comprises an intracellular domain of OX40, and the transmembrane domain comprises a transmembrane domain of Fas;
the extracellular domain comprises an extracellular domain of Fas, the intracellular domain comprises an intracellular domain of OX40, and the transmembrane domain comprises a transmembrane domain of OX40;
the extracellular domain comprises an extracellular domain of CD200R, the intracellular domain comprises an intracellular domain of ICOS, and the transmembrane domain comprises a transmembrane domain of CD28;
the extracellular domain comprises an extracellular domain of CD200R, the intracellular domain comprises an intracellular domain of SLAMF1, and the transmembrane domain comprises a transmembrane domain of CD28;
the extracellular domain comprises an extracellular domain of SIRPα, the intracellular domain comprises an intracellular domain of ICOS, and the transmembrane domain comprises a transmembrane domain of CD28; or
the extracellular domain comprises an extracellular domain of SIRPα, the intracellular domain comprises an intracellular domain of SLAMF1, and the transmembrane domain comprises a transmembrane domain of CD28.

### Claim 9 (depends on 7)

The protein of claim 7, having the sequence as set forth in SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 109, or SEQ ID NO: 110
or a sequence having at least 90% or 95% sequence identity to the sequence as set forth in SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 109, or SEQ ID NO: 110.

### Claim 10 (depends on 1)

The protein of claim 1, wherein the transmembrane domain comprises the transmembrane domain of Fas, HVEM, CD28, 4-1BB, CD27, CD30, CD40, DR3, GITR, or OX40.

### Claim 11 (depends on 1)

The protein of claim 1, wherein the transmembrane domain comprises the sequence as set forth in SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 19, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, or SEQ ID NO: 20
or a sequence having at least 90% or 95% sequence identity to the sequence as set forth in SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 19, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, or SEQ ID NO: 20.

### Claim 12 (depends on 1)

The protein of claim 1, wherein the transmembrane domain is encoded by the sequence as set forth in SEQ ID NO: 8 or a sequence having at least 90% or 95% sequence identity to the sequence as set forth in SEQ ID NO: 8.

### Claim 13 (depends on 1)

The protein of claim 1, wherein the intracellular domain of the stimulatory immune cell protein is inverted.

### Claim 14 (depends on 13)

The protein of claim 13, wherein the inverted intracellular domain is LIGHT.

### Claim 15 (depends on 1)

The protein of claim 1, wherein expression of the protein by an immune cell causes activation of the immune cell in the presence of a ligand, whereas an immune cell that does not express the protein has an inhibitory response in the presence of the same ligand.

### Claim 16 (depends on 1)

The protein of claim 1, wherein the Fas is an huFas or an muFas.

### Claim 17 (depends on 1)

The protein of claim 1, wherein the CD200R is an huCD200R or an muCD200R.

### Claim 18 (depends on 1)

The protein of claim 1, wherein the SIRPα is an huSIRPα.

### Claim 19 (depends on 16)

The protein of claim 16, wherein the Fas comprises the sequence as set forth in SEQ ID NO: 5 or SEQ ID NO: 6 or a sequence having at least 90% or 95% sequence identity to the sequence as set forth in SEQ ID NO: 5 or SEQ ID NO: 6.

### Claim 20 (depends on 17)

The protein of claim 17, wherein the huCD200R comprises the sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 4 or a sequence having at least 90% or 95% sequence identity to the sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 4.

### Claim 21 (depends on 17)

The protein of claim 17, wherein the muCD200R comprises the sequence as set forth in SEQ ID NO: 2 or a sequence having at least 90% or 95% sequence identity to the sequence as set forth in SEQ ID NO: 2.

### Claim 22 (depends on 17)

The protein of claim 17, wherein the muCD200R is encoded by the sequence as set forth in SEQ ID NO: 1 or a sequence having at least 90% or 95% sequence identity to the sequence as set forth in SEQ ID NO: 1.

### Claim 23 (depends on 18)

The protein of claim 18, wherein the SIRPα comprises the sequence as set forth in SEQ ID NO: 7 a sequence having at least 90% or 95% sequence identity to the sequence as set forth in SEQ ID NO: 7.

### Claim 24 (depends on 1)

The protein of claim 1, further comprising junction amino acids.

### Claim 25 (depends on 24)

The protein of claim 24, wherein the junction amino acids comprise the sequence as set forth in SEQ ID NO: 78, SEQ ID NO: 79, or SEQ ID NO: 80
or a sequence having at least 90% or 95% sequence identity to the sequence as set forth in SEQ ID NO: 78, SEQ ID NO: 79, or SEQ ID NO: 80.

### Claim 26 (depends on 1)

The protein of claim 1, further comprising at least a second intracellular domain, the at least second intracellular domain also linked to the extracellular domain through the transmembrane domain.

### Claim 27 (depends on 1)

The protein of claim 1, wherein the protein further comprises a multimerization domain.

### Claim 28 (depends on 27)

The protein of claim 27, wherein the multimerization domain is part of a chemically-induced dimerization system or a chemically-induced trimerization system.

### Claim 29 (depends on 1)

A nucleotide comprising a gene encoding a protein of claim 1.

### Claim 30 (depends on 1, 29)

The nucleotide of claim 29, comprising a second gene encoding a second protein of any of claim 1.

### Claim 31 (depends on 30)

The nucleotide of claim 30, wherein the gene encodes Fas-HVEM and the second gene encodes Fas-CD40, Fas-CD27, or SIRPα-ICOS.

### Claim 32 (depends on 30)

The nucleotide of claim 30, wherein the gene encodes Fas-CD40 and the second gene encodes Fas-HVEM, Fas-CD27, or SIRPα-ICOS.

### Claim 33 (depends on 30)

The nucleotide of claim 30, wherein the gene encodes Fas-CD27 and the second gene encodes Fas-HVEM, Fas-CD40, or SIRPα-ICOS.

### Claim 34 (depends on 30)

The nucleotide of claim 30, wherein the gene encodes SIRPα-ICOS and the second gene encodes Fas-CD40, Fas-CD27, or Fas-HVEM.

### Claim 35 (depends on 1, 30)

The nucleotide of claim 30, comprising a third gene encoding a third protein of claim 1.

### Claim 36 (depends on 29)

The nucleotide of claim 29, wherein the nucleotide comprises regulatory elements comprising an inducible promoter.

### Claim 37 (depends on 30)

The nucleotide of claim 30, wherein the first gene and the second gene are under the regulatory control of different inducible promoters.

### Claim 38 (depends on 35)

The nucleotide of claim 35, wherein the first gene, the second gene, and the third gene are under the regulatory control of different inducible promoters.

### Claim 39 (depends on 1)

A cell genetically modified to express a protein of claim 1.

### Claim 40 (depends on 1, 39)

A cell of claim 39, genetically modified to express a second protein of claim 1.

### Claim 41 (depends on 40)

The cell of claim 40, wherein the first protein comprises Fas-HVEM and the second protein comprises Fas-CD40, Fas-CD27, or SIRPα-ICOS.

### Claim 42 (depends on 40)

The cell of claim 40, wherein the first protein comprises Fas-CD40 and the second protein comprises Fas-HVEM, Fas-CD27, or SIRPα-ICOS.

### Claim 43 (depends on 40)

The cell of claim 40, wherein the first protein comprises Fas-CD27 and the second protein comprises Fas-HVEM, Fas-CD40, or SIRPα-ICOS.

### Claim 44 (depends on 40)

The cell of claim 40, wherein the first protein comprises SIRPα-ICOS and the protein comprises encodes Fas-CD40, Fas-CD27, or Fas-HVEM.

### Claim 45 (depends on 1, 39)

The cell of claim 39, genetically modified to express a third protein of claim 1.

### Claim 46 (depends on 39)

The cell of claim 39, wherein the cell is an immune cell.

### Claim 47 (depends on 39)

The cell of claim 39, wherein the cell is a T cell or a natural killer (NK) cell.

### Claim 48 (depends on 47)

The cell of claim 47, wherein the T cell is a CD4+ or a CD8+ T cell.

### Claim 49 (depends on 39)

The cell of claim 39, wherein the cell is an induced pluripotent stem cell (iPSC), a tumor-infiltrating lymphocyte (TIL), a marrow-infiltrating lymphocyte (MIL), a natural killer T cell (NKT), a mucosal-associated invariant T (MAIT) cell, a B cell, a dendritic cell, a monocyte or a macrophage.

### Claim 50 (depends on 1, 29)

A method of genetically-modifying an immune cell to express a protein of claim 1 comprising introducing a nucleotide of claim 29 into the immune cell.

### Claim 51 (depends on 39)

A formulation comprising a cell of claim 39 and a pharmaceutically acceptable carrier.

### Claim 52 (depends on 29)

A nanoparticle comprising a nucleotide of claim 29.

### Claim 53 (depends on 52)

The nanoparticle of claim 52, further comprising a cell targeting ligand.

### Claim 54 (depends on 53)

The nanoparticle of claim 53, wherein the cell targeting ligand binds a T cell surface marker.

### Claim 55 (depends on 54)

The nanoparticle of claim 54, wherein the T cell surface marker is CD3, CD4, or CD8.

### Claim 56 (depends on 53)

The nanoparticle of claim 53, wherein the cell targeting ligand binds an iPSC marker, a TIL marker, a MIL marker, an NKT marker, a MAIT cell marker, a B cell marker, a dendritic cell marker, a monocyte marker, or a macrophage marker.

### Claim 57 (depends on 52)

A composition comprising a nanoparticle of claim 52 and a pharmaceutically acceptable carrier.

### Claim 58 (depends on 29, 51, 52)

A method of stimulating an immune response in a subject in need thereof comprising administering a therapeutically effective amount of a nucleotide of claim 29, a formulation of claim 51, or a nanoparticle of claim 52 to the subject, thereby stimulating the immune response in the subject thereof.

### Claim 59 (depends on 58)

The method of claim 58, wherein the stimulating increases stimulatory intracellular signaling in immune cells within the subject in the presence of inhibitory signals.

### Claim 60 (depends on 59)

The method of claim 59, wherein the increased stimulatory intracellular signaling in immune cells within the subject results in increased immune cell proliferation and/or increased immune cell activation in the subject, as compared to a comparable subject who was not administered the therapeutically effective amount.

### Claim 61 (depends on 58)

The method of claim 58, wherein the stimulating provides an anti-cancer effect or an anti-infection effect in the subject.
